Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder (TACGAD)
Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200065
- Shanghai Tongji Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-65 years old
- Male or female
- Diagnosed with GAD according to DSM-IV
- HAMA score≥17
- Provide with written informed consent
- Agree to be washed-out for two weeks if receiving SSRI, SNRI or NASA.
Exclusion Criteria:
- Serious suicidal tendency
- The score of the sixth item of HAMA ≥3
- The score of HAMD ≥21
- Pregnant or lactating women
- History of allergic or hypersensitivity to tandospirone
- Serious or unstable cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease
- Secondary anxiety disorders
- Drug or alcohol dependence within 1 year
- Patients currently taking benzodiazepine drugs
- Drivers and dangerous machine operators
- Participated in other clinical studies in the last 30 days
- Patients with clinically significant ECG or laboratory abnormalities
- Patients with a history of epilepsy
- Patients with abnormal TSH concentration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control Group
Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
|
Usual dose treatment of Tandospirone, oral, 30 mg/day
|
|
Experimental: Study Group
Comparative high dose of tandospirone treatment, 60 mg/day
|
Comparative high dose of tandospirone treatment, oral, 60 mg/day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients whose Hamilton Anxiety Scale (HAMA) score change downwards ≥ 50% from baseline to 6 weeks treatment
Time Frame: 6 weeks
|
HAMA score changes downwards ≥ 50% indicate significant improvement; HAMA score changes downwards ≥ 75% indicate remission
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HAMA score changes from baseline to 6 weeks treatment
Time Frame: 6 weeks
|
Scores 14-21 indicate mild anxiety; scores 21-29 indicate moderate anxiety; scores over 29 indicate severe anxiety
|
6 weeks
|
|
Percentage of patients whose HAMA score ≤ 7 after 6 weeks treatment
Time Frame: 6 weeks
|
Scores ≤ 7 indicate non-anxious
|
6 weeks
|
|
HAMA factor score changes after treatment
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wenyuan Wu, MD, Shanghai Tongji Hospital, Tongji University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Disease
- Anxiety Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Receptor Agonists
- Anti-Anxiety Agents
- Tandospirone
Other Study ID Numbers
Other Study ID Numbers
- DSPC-SED-1101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.